Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: The FARO-2 study

Daniela Paola Roggeri, Mario Cozzolino, Sandro Mazzaferro, Diego Brancaccio, Ernesto Paoletti, Alessandro Roggeri, Anna Maria Costanzo, Umberto di Luzio Paparatti, Vincenzo Festa, Piergiorgio Messa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Results: Two prominent treatment groups were identified, ie, one on oral calcitriol (n=105) and the other on intravenous paricalcitol (n=33); the intravenous calcitriol and intravenous paricalcitol + cinacalcet combination groups were not analyzed due to low patient numbers. At baseline, serum PTH levels were significantly higher in the intravenous paricalcitol group (P

Conclusion: Intravenous paricalcitol significantly increased the percentage of patients at target for the combined endpoint of PTH, calcium, and phosphate (P=0.001). The total cost of treatment for the patients treated with intravenous paricalcitol 6 months after entry to dialysis was not significantly higher than the cost for patients treated with oral calcitriol.

Background: The aim of this analysis was to estimate biochemical parameters and the costs of treatment of secondary hyperparathyroidism (SHPT) in a subpopulation of the FARO-2 study.

Methods: The FARO-2 observational study aimed at evaluating the patterns of treatment for SHPT in naïve hemodialysis patients. Data related to pharmacological treatments and biochemical parameters (parathyroid hormone [PTH], calcium, phosphate) were recorded at entry to hemodialysis (baseline) and 6 months later (second survey). The analysis was performed from the Italian National Health Service perspective.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalInternational Journal of Nephrology and Renovascular Disease
Volume8
DOIs
Publication statusPublished - Dec 16 2014

Fingerprint

Secondary Hyperparathyroidism
Health Care Costs
Dialysis
Calcitriol
Parathyroid Hormone
Renal Dialysis
National Health Programs
Observational Studies
Therapeutics
paricalcitol
Pharmacology
Costs and Cost Analysis
Serum

Keywords

  • Cost consequences analysis
  • Outcomes
  • Secondary hyperparathyroidism
  • SHPT treatments
  • Therapeutic costs

ASJC Scopus subject areas

  • Nephrology

Cite this

Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients : The FARO-2 study. / Roggeri, Daniela Paola; Cozzolino, Mario; Mazzaferro, Sandro; Brancaccio, Diego; Paoletti, Ernesto; Roggeri, Alessandro; Costanzo, Anna Maria; Paparatti, Umberto di Luzio; Festa, Vincenzo; Messa, Piergiorgio.

In: International Journal of Nephrology and Renovascular Disease, Vol. 8, 16.12.2014, p. 1-6.

Research output: Contribution to journalArticle

Roggeri, Daniela Paola ; Cozzolino, Mario ; Mazzaferro, Sandro ; Brancaccio, Diego ; Paoletti, Ernesto ; Roggeri, Alessandro ; Costanzo, Anna Maria ; Paparatti, Umberto di Luzio ; Festa, Vincenzo ; Messa, Piergiorgio. / Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients : The FARO-2 study. In: International Journal of Nephrology and Renovascular Disease. 2014 ; Vol. 8. pp. 1-6.
@article{fb724f33358e4296914f641dbaac01a0,
title = "Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: The FARO-2 study",
abstract = "Results: Two prominent treatment groups were identified, ie, one on oral calcitriol (n=105) and the other on intravenous paricalcitol (n=33); the intravenous calcitriol and intravenous paricalcitol + cinacalcet combination groups were not analyzed due to low patient numbers. At baseline, serum PTH levels were significantly higher in the intravenous paricalcitol group (PConclusion: Intravenous paricalcitol significantly increased the percentage of patients at target for the combined endpoint of PTH, calcium, and phosphate (P=0.001). The total cost of treatment for the patients treated with intravenous paricalcitol 6 months after entry to dialysis was not significantly higher than the cost for patients treated with oral calcitriol.Background: The aim of this analysis was to estimate biochemical parameters and the costs of treatment of secondary hyperparathyroidism (SHPT) in a subpopulation of the FARO-2 study.Methods: The FARO-2 observational study aimed at evaluating the patterns of treatment for SHPT in na{\"i}ve hemodialysis patients. Data related to pharmacological treatments and biochemical parameters (parathyroid hormone [PTH], calcium, phosphate) were recorded at entry to hemodialysis (baseline) and 6 months later (second survey). The analysis was performed from the Italian National Health Service perspective.",
keywords = "Cost consequences analysis, Outcomes, Secondary hyperparathyroidism, SHPT treatments, Therapeutic costs",
author = "Roggeri, {Daniela Paola} and Mario Cozzolino and Sandro Mazzaferro and Diego Brancaccio and Ernesto Paoletti and Alessandro Roggeri and Costanzo, {Anna Maria} and Paparatti, {Umberto di Luzio} and Vincenzo Festa and Piergiorgio Messa",
year = "2014",
month = "12",
day = "16",
doi = "10.2147/IJNRD.S72011",
language = "English",
volume = "8",
pages = "1--6",
journal = "International Journal of Nephrology and Renovascular Disease",
issn = "1178-7058",
publisher = "Dove Medical Press Limited",

}

TY - JOUR

T1 - Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients

T2 - The FARO-2 study

AU - Roggeri, Daniela Paola

AU - Cozzolino, Mario

AU - Mazzaferro, Sandro

AU - Brancaccio, Diego

AU - Paoletti, Ernesto

AU - Roggeri, Alessandro

AU - Costanzo, Anna Maria

AU - Paparatti, Umberto di Luzio

AU - Festa, Vincenzo

AU - Messa, Piergiorgio

PY - 2014/12/16

Y1 - 2014/12/16

N2 - Results: Two prominent treatment groups were identified, ie, one on oral calcitriol (n=105) and the other on intravenous paricalcitol (n=33); the intravenous calcitriol and intravenous paricalcitol + cinacalcet combination groups were not analyzed due to low patient numbers. At baseline, serum PTH levels were significantly higher in the intravenous paricalcitol group (PConclusion: Intravenous paricalcitol significantly increased the percentage of patients at target for the combined endpoint of PTH, calcium, and phosphate (P=0.001). The total cost of treatment for the patients treated with intravenous paricalcitol 6 months after entry to dialysis was not significantly higher than the cost for patients treated with oral calcitriol.Background: The aim of this analysis was to estimate biochemical parameters and the costs of treatment of secondary hyperparathyroidism (SHPT) in a subpopulation of the FARO-2 study.Methods: The FARO-2 observational study aimed at evaluating the patterns of treatment for SHPT in naïve hemodialysis patients. Data related to pharmacological treatments and biochemical parameters (parathyroid hormone [PTH], calcium, phosphate) were recorded at entry to hemodialysis (baseline) and 6 months later (second survey). The analysis was performed from the Italian National Health Service perspective.

AB - Results: Two prominent treatment groups were identified, ie, one on oral calcitriol (n=105) and the other on intravenous paricalcitol (n=33); the intravenous calcitriol and intravenous paricalcitol + cinacalcet combination groups were not analyzed due to low patient numbers. At baseline, serum PTH levels were significantly higher in the intravenous paricalcitol group (PConclusion: Intravenous paricalcitol significantly increased the percentage of patients at target for the combined endpoint of PTH, calcium, and phosphate (P=0.001). The total cost of treatment for the patients treated with intravenous paricalcitol 6 months after entry to dialysis was not significantly higher than the cost for patients treated with oral calcitriol.Background: The aim of this analysis was to estimate biochemical parameters and the costs of treatment of secondary hyperparathyroidism (SHPT) in a subpopulation of the FARO-2 study.Methods: The FARO-2 observational study aimed at evaluating the patterns of treatment for SHPT in naïve hemodialysis patients. Data related to pharmacological treatments and biochemical parameters (parathyroid hormone [PTH], calcium, phosphate) were recorded at entry to hemodialysis (baseline) and 6 months later (second survey). The analysis was performed from the Italian National Health Service perspective.

KW - Cost consequences analysis

KW - Outcomes

KW - Secondary hyperparathyroidism

KW - SHPT treatments

KW - Therapeutic costs

UR - http://www.scopus.com/inward/record.url?scp=84919679892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919679892&partnerID=8YFLogxK

U2 - 10.2147/IJNRD.S72011

DO - 10.2147/IJNRD.S72011

M3 - Article

AN - SCOPUS:84919679892

VL - 8

SP - 1

EP - 6

JO - International Journal of Nephrology and Renovascular Disease

JF - International Journal of Nephrology and Renovascular Disease

SN - 1178-7058

ER -